| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS) |
| Creator | Adenis et al. |
| Author | A. Adenis |
| Author | J. Bennouna |
| Author | P. L. Etienne |
| Author | E. Bogart |
| Author | E. Francois |
| Author | M. P. Galais |
| Author | M. Ben Abdelghani |
| Author | P. Michel |
| Author | J. P. Metges |
| Author | L. Dahan |
| Author | T. Conroy |
| Author | F. Ghiringhelli |
| Author | A. Drouillard |
| Author | F. El Hajbi |
| Author | E. Samalin |
| Author | S. Hiret |
| Author | S. Delaine-Clisant |
| Author | C. Mariette |
| Author | N. Penel |
| Author | G. Piessen |
| Author | M. C. Le Deley |
| Abstract | PURPOSE: The role of chemotherapy has not been established in the treatment of metastatic squamous cell oesophageal cancer (mESCC). PATIENTS AND METHODS: E-DIS is a discontinuation trial, aimed at estimating efficacy, quality of life and safety of chemotherapy continuation (CT-CONT) in patients with mESCC who are free from progression after a selection phase of chemotherapy. The primary end-point was overall survival. RESULTS: Sixty-seven patients were randomised. The 9-month survival rate was 50% (85% confidence interval [CI]: 37-62%) and 48% (85% CI: 35-60%) in the CT-CONT arm and in the chemotherapy discontinuation (CT-DISC) arm, respectively. The time until definitive deterioration of the global health status (European Organisation for Research and Treatment of Cancer [EORTC] core quality of life questionnaire) was 6.6 months (95% CI: 3.3-12.4) for the CT-CONT arm and 4.2 months (95% CI: 2.9-6.3) for the CT-DISC arm, with a hazard ratio (HRCT-DISC/CT-CONT) = 1.44 (95% CI: 0.82-2.53). We observed a beneficial trend in favour of CT-CONT (HR > 1) for most dimensions, including an improvement for three dimensions (dysphagia, eating and oesophageal pain) of the EORTC Oesophageal Cancer Module QLQ-OES18. CONCLUSION: CT-CONT provides an overall survival rate that is similar to CT-DISC. E-DIS trial provides valuable data to support shared decision-making between physicians and patients regarding CT-CONT/DISC. |
| Publication | European Journal of Cancer (Oxford, England: 1990) |
| Volume | 111 |
| Pages | 12-20 |
| Date | Feb 21, 2019 |
| Journal Abbr | Eur. J. Cancer |
| Language | eng |
| DOI | 10.1016/j.ejca.2019.01.016 |
| ISSN | 1879-0852 |
| Short Title | Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer |
| Library Catalog | PubMed |
| Extra | PMID: 30798084 |
| Tags | Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, clinic, Disease Progression, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Female, Humans, Male, Metastatic disease, Middle Aged, Oesophageal cancer, Progression-Free Survival, Treatment Outcome |
| Date Added | 2019/03/14 - 12:50:06 |
| Date Modified | 2020/06/04 - 14:53:41 |
| Notes and Attachments | PubMed entry (Attachment) PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
